Four buy­outs (and one ru­mor that didn’t ma­te­ri­al­ize); Iso­mor­phic Lab­s' first phar­ma deals; A CAR-T IPO; #JPM24 high­lights; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

From what I’ve heard from my col­leagues in San Fran­cis­co, it’s been a busy but fruit­ful JPM con­fer­ence for End­points. Thank you to every­one who joined our events or shared your in­sights with us — we’ll see you next year!

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER